Industry by country
Pharmaceutical Products companies in United States
VCMC tracks 5,252 companies in Pharmaceutical Products based in United States. 507 of them have raised a venture or growth round, $40.40B in total, with a median round of $25M; 195 raised since 2024. 488 of the 507 have a VCMC valuation; the median is $144M.
5,252
companies tracked
507
venture-backed
10% of those tracked
$40.40B
raised in total
by 487 companies
$25M
median round
of 739 rounds with an amount
$144M
median valuation
of 488 companies valued
Values cover private companies only; public companies are not included.
By their latest round, most are at Series A (165 of 507).
- Pre-seed 7
- Seed 73
- Series A 165
- Series B 113
- Series C and later 145
- Stage not stated 4
The companies
Pharmaceutical Products companies in United States
The 50 venture-backed companies below are this page's list; Resilience has raised the most ($2.02B).
| # | Last round | History | Range | Trend | Grade | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Resilience Blue Ash | Series D Jun 2022 $625M | $3.3B | $633M – $13.0B | $2.8B (-13%) | $1.1B | 59% | 1,307 | flat | D | |
| 2 | ElevateBio Waltham | Series D May 2023 $401M | $2.4B | $693M – $9.9B | $1.7B (-30%) | $720M | 79% | 450 | down | D | |
| 3 | Cerevel Cambridge | Debt Aug 2022 $300M | $755M | $100M – $2.4B | $679M (-10%) | $151M | 46% | 140 | unknown | D | |
| 4 | Azurity Pharmaceuticals Woburn | Growth Equity Mar 2026 $1.10B | $13.3B | $8.4B – $21.3B | $14.0B (+6%) | $1.3B | 0% | 1,062 | growing | B | |
| 5 | Kailera Therapeutics Waltham | Series B Oct 2025 $600M | $5.5B | $2.6B – $7.8B | $5.5B (0%) | $608M | 0% | 26 | unknown | B | |
| 6 | Cellares South San Francisco | Series D Jan 2026 $257M | $4.0B | $2.3B – $6.1B | $4.3B (+8%) | $470M | 0% | 327 | up | B | |
| 7 | Nimbus Therapeutics Boston | Growth Equity Sep 2023 $210M | $1.2B | $283M – $2.9B | $1.0B (-14%) | $197M | 28% | 102 | flat | D | |
| 8 | Formation Bio New York | Series D Jun 2024 $372M | $6.0B | $1.5B – $8.5B | $4.0B (-34%) | $660M | 0% | 198 | flat | C | |
| 9 | Rakuten Medical San Diego | Series F Jan 2026 $100M | $1.6B | $973M – $2.4B | $1.6B (0%) | $197M | 21% | 132 | flat | B | |
| 10 | Sail Biomedicines Cambridge | Growth Equity Jul 2026 $465M | $5.2B | $3.4B – $8.1B | $5.0B (-3%) | $512M | 67% | 108 | flat | B | |
| 11 | Abcuro Newton | Series D Aug 2026 $66M | $826M | $542M – $1.3B | $770M (-7%) | $118M | 97% | 36 | shrinking | B | |
| 12 | Synthego Redwood City | Series E Feb 2022 $200M | $1.5B | $115M – $3.3B | $1.5B (-1%) | $252M | 16% | 163 | unknown | D | |
| 13 | Orca Bio Menlo Park | Debt Jan 2026 | $4.1B | $2.2B – $6.6B | $4.3B (+6%) | $475M | 0% | 377 | growing | B | |
| 14 | Ollin Biosciences Austin | Series B Jun 2026 $330M | $2.0B | $1.2B – $3.6B | $2.6B (+31%) | $283M | 0% | 28 | unknown | B | |
| 15 | Westlake Village | Series D Feb 2026 $130M | $1.9B | $1.1B – $2.9B | $2.1B (+9%) | $226M | 0% | 65 | growing | B | |
| 16 | Natick | Growth Equity May 2026 $250M | $2.9B | $1.8B – $4.7B | $3.1B (+5%) | $275M | 0% | 5 | unknown | B | |
| 17 | Series A Jan 2025 $180M | $1.8B | $410M – $2.7B | $1.8B (0%) | $252M | 0% | 7 | unknown | C | ||
| 18 | Framingham | Series E Jun 2024 $100M | $1.1B | $363M – $2.1B | $622M (-45%) | $167M | 43% | 30 | flat | C | |
| 19 | Santa Clarita | Series C Oct 2024 $115M | $1.1B | $377M – $2.0B | $780M (-26%) | $155M | 51% | 166 | down | C | |
| 20 | Needham | Series C Jun 2022 $120M | $199M | $92.6M – $689M | $153M (-23%) | $148M | 97% | 59 | shrinking | D | |
| 21 | Nocatee | Series D Oct 2024 $68M | $728M | $344M – $1.7B | $372M (-49%) | $140M | 97% | 68 | down | C | |
| 22 | Fontana | Growth Equity Apr 2021 $100M | $1.2B | $73.0M – $1.9B | $1.2B (0%) | $110M | 0% | 3 | unknown | D | |
| 23 | Concord | Debt Jan 2022 $10M | $98.0M | $21.8M – $811M | $86.5M (-12%) | $104M | 82% | 24 | down | D | |
| 24 | Tarrytown | Series B May 2022 $41M | $43.8M | $22.3M – $134M | $35.4M (-19%) | $48.3M | 97% | 23 | shrinking | C | |
| 25 | Weston | Series D Sep 2022 $43M | $526M | $72.6M – $1.2B | $522M (-1%) | $91.1M | 0% | 31 | up | D | |
| 26 | Novato | Series A Apr 2026 $12M | $88.9M | $43.8M – $183M | $120M (+35%) | $16.8M | 0% | 12 | flat | C | |
| 27 | Lexington | Series A Feb 2018 $60M | $204M | $21.9M – $493M | $198M (-3%) | $84.0M | 30% | 190 | flat | D | |
| 28 | Richmond | Series A Oct 2020 $60M | $66.2M | $21.9M – $230M | $63.3M (-4%) | $84.0M | 97% | 46 | shrinking | D | |
| 29 | Shelton | Series A Jun 2022 $60M | $530M | $28.5M – $807M | $485M (-8%) | $84.0M | 0% | 21 | flat | D | |
| 30 | Series A Jan 2026 $60M | $513M | $219M – $913M | $600M (+17%) | $84.0M | 0% | 17 | unknown | C | ||
| 31 | Series A Jun 2022 $60M | $600M | $28.9M – $913M | $600M (0%) | $84.0M | 0% | 7 | unknown | D | ||
| 32 | Gainesville | Series A May 2025 $22M | $239M | $94.2M – $364M | $239M (0%) | $33.5M | 0% | 97 | growing | C | |
| 33 | Calabasas | Acquisition Jan 2025 $45M | $93.7M acquired 2025 | $9.45M – $178M | – | – | 20% | 28 | flat | D | |
| 34 | Palm Beach Gardens | Series A Nov 2023 $50M | $690M | $124M – $1.1B | $392M (-43%) | $96.6M | 0% | 13 | up | D | |
| 35 | Series A Feb 2023 $40M | $199M | $30.0M – $514M | $158M (-20%) | $56.9M | 40% | 14 | flat | D | ||
| 36 | Richmond | Series B Mar 2024 $22M | $173M | $43.0M – $332M | $108M (-37%) | $26.5M | 38% | 31 | flat | D | |
| 37 | Fort Worth | Series C May 2025 $26M | $300M | $148M – $469M | $285M (-5%) | $35.0M | 16% | 31 | up | B | |
| 38 | Duarte | Series D Dec 2016 $15M | $159M | $12.1M – $279M | $159M (0%) | $26.8M | 8% | 325 | flat | D | |
| 39 | Growth Equity Apr 2021 $30M | $189M | $22.3M – $1.1B | $171M (-10%) | $33.5M | 86% | 230 | down | D | ||
| 40 | Lexington | Series A Oct 2020 $30M | $63.7M | $8.99M – $305M | $56.9M (-11%) | $39.2M | 56% | 11 | flat | D | |
| 41 | Series A Dec 2024 $27M | $270M | $58.7M – $411M | $270M (0%) | $37.8M | 0% | 37 | unknown | C | ||
| 42 | Mission Viejo | Series A May 2013 $23M | $209M | $7.64M – $350M | $209M (0%) | $32.2M | 0% | 1,000 | unknown | D | |
| 43 | Pearl River | Growth Equity Oct 2025 $25M | $314M | $187M – $479M | $314M (0%) | $28.3M | 0% | 106 | up | B | |
| 44 | Spokane | Seed Sep 2023 $24M | $1.02M | $0 – $1.02M | $1.02M (0%) | – | 100% | 10 | shrinking | dead | |
| 45 | Newark | Series B Sep 2023 $23M | $202M | $25.6M – $451M | $187M (-7%) | $32.9M | 1% | 12 | flat | D | |
| 46 | Delray Beach | Series B Jan 2024 $9.0M | $96.4M | $14.6M – $147M | $66.1M (-31%) | $10.6M | 0% | 6 | unknown | D | |
| 47 | Novato | Series A Jan 2025 $6.4M | $63.3M | $26.9M – $101M | $60.0M (-5%) | $9.74M | 12% | 19 | growing | C | |
| 48 | Series A Jun 2026 $20M | $135M | $73.0M – $304M | $200M (+48%) | $28.0M | 0% | 30 | unknown | C | ||
| 49 | Castroville | Series A Oct 2022 $20M | $146M | $8.54M – $304M | $146M (0%) | $28.0M | 0% | 22 | unknown | D | |
| 50 | Solana Beach | Series B Feb 2023 $20M | $1.43M | $0 – $1.43M | $1.43M (0%) | – | 100% | 7 | unknown | dead |
Showing 50 of 5,252. Load more lists every other company here, 50 at a time.
Valuations
How these companies are valued
488 of the 507 venture-backed companies here have a VCMC valuation; the median is $144M. A company acquired after its last round keeps its last value as a private company and is left out of the median. 16 companies have disclosed a valuation; for the rest VCMC's valuation is the only number. Each valuation comes with a range, from a low to a high scenario, and a prediction for a year from now. Values cover private companies only; public companies are not included. How VCMC values companies.
Investors
Who backs them
Firms that backed two or more of these companies. RA Capital backed 30, Alexandria Venture Investments 19.
- 30 companies, led 7
- Alexandria Venture Investments 19 companies, led 1
- 17 companies, led 3
- ARCH Venture Partners 12 companies, led 4
- 12 companies, led 4
- 12 companies, led 4
- 12 companies, led 2
- Bain Capital Life Sciences 10 companies, led 5
- New Enterprise Associates 10 companies, led 5
- GV 10 companies, led 2
- 9 companies, led 4
- 9 companies, led 3
Recent rounds
Latest funding
80 rounds from Oct 2025 to Sep 2026, $7.01B with a disclosed amount.
- Series B, led by DeepWork Capital $9.5M 30 Sep 2026
- Pre-seed, with Elmstead Partners and Chisos Capital $2.4M 25 Sep 2026
- Series C, led by Forbion $123M 16 Sep 2026
- Seed $1.8M 10 Sep 2026
- Seed, led by RRE Ventures $7.1M 4 Sep 2026
- Series A, led by Company K Partners $14M 19 Aug 2026
- Abcuro Series D, led by New Leaf Venture Partners $66M 18 Aug 2026
- Series B, led by General Atlantic $115M 5 Aug 2026
- Growth, led by Asymchem Group $184M 4 Aug 2026
- Series C, with Duquesne Family Office and Bristol Myers Squibb $70M 31 Jul 2026
- Sail Biomedicines Growth, with Johnson & Johnson $465M 29 Jul 2026
- Series B, led by Frazier Life Sciences $130M 22 Jul 2026
Browse
Related groups
Wider groups
Pharmaceutical Products in other countries
Other industries in United States
Questions
Frequently asked
How many pharmaceutical Products companies in United States does VCMC track?
5,252. 507 of them have raised a venture or growth round.
How much have pharmaceutical Products companies in United States raised?
$40.40B in total across the 487 with a known amount; the median round is $25M. 195 raised a round since 2024.
Which pharmaceutical Products companies in United States have raised the most?
Resilience ($2.02B), ElevateBio ($1.25B), Cerevel ($1.22B).
Which investors back pharmaceutical Products companies in United States most often?
RA Capital (30 companies), Alexandria Venture Investments (19 companies), OrbiMed (17 companies).
What are pharmaceutical Products companies in United States worth?
The median VCMC valuation is $144M across 488 companies; companies acquired after their last round are left out. Values cover private companies only; public companies are not included.
What was the latest funding round?
Astrocyte Pharmaceuticals raised a Series B round of $9.5M (Sep 2026), led by DeepWork Capital.